These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26559996)

  • 1. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.
    Huang B; Kang D; Yang J; Zhan P; Liu X
    Expert Opin Ther Pat; 2016; 26(2):281-9. PubMed ID: 26559996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Tian XT; Xie L
    Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2).
    Huang B; Zhou Z; Kang D; Li W; Chen Z; Zhan P; Liu X
    Expert Opin Ther Pat; 2017 Jan; 27(1):9-15. PubMed ID: 27855563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419.
    Meng Q; Liu N; Huang B; Zhan P; Liu X
    Expert Opin Ther Pat; 2015; 25(12):1477-86. PubMed ID: 26415039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1.
    Kang D; Huo Z; Wu G; Xu J; Zhan P; Liu X
    Expert Opin Ther Pat; 2017 Apr; 27(4):383-391. PubMed ID: 28276283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-nucleoside reverse transcriptase inhibitors (Part 18): synthesis and anti-HIV activity of 4-allylamino or 4-azido substituted diaryltriazines.
    Xiong YZ; Hu HR; Chen FE; Balzarini J; Pannecouque C; de Clercq E
    Yao Xue Xue Bao; 2009 Feb; 44(2):145-9. PubMed ID: 19408683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors.
    Liu Y; Meng G; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Pharm Sci; 2014 Oct; 62():334-41. PubMed ID: 24956462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
    Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
    Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues.
    Ludovici DW; Kavash RW; Kukla MJ; Ho CY; Ye H; De Corte BL; Andries K; de Béthune MP; Azijn H; Pauwels R; Moereels HE; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Lewi PJ; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2229-34. PubMed ID: 11527704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
    Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Jan; 185():111874. PubMed ID: 31735575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
    Jin X; Piao HR; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2021 Dec; 226():113868. PubMed ID: 34583311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain.
    Xiong YZ; Chen FE; Balzarini J; De Clercq E; Pannecouque C
    Chem Biodivers; 2009 Apr; 6(4):561-8. PubMed ID: 19353537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
    Jiang X; Huang B; Olotu FA; Li J; Kang D; Wang Z; De Clercq E; Soliman MES; Pannecouque C; Liu X; Zhan P
    Eur J Med Chem; 2021 Mar; 213():113051. PubMed ID: 33279288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
    Gu SX; Yang SQ; He QQ; Ma XD; Chen FE; Dai HF; Clercq ED; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Dec; 19(23):7093-9. PubMed ID: 22037050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase.
    Mislak AC; Frey KM; Bollini M; Jorgensen WL; Anderson KS
    Biochim Biophys Acta; 2014 Jul; 1840(7):2203-11. PubMed ID: 24726448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.